Therapy Detail

Therapy Name Ipafricept
Synonym
Therapy Description

Ipafricept (OMP-54F28) is a fusion protein comprised of the ligand binding domain of the Frizzled family receptor 8 and the human immunoglobulin Fc domain, which binds Wnt and prevents downstream signaling, thereby inhibiting tumor growth (PMID: 25172549).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Ipafricept Fzd8-Fc|OMP-54F28 WNT Inhibitor 9 Ipafricept (OMP-54F28) is a fusion protein comprised of the ligand binding domain of the Frizzled family receptor 8 and the human immunoglobulin Fc domain, which binds Wnt and prevents downstream signaling, thereby inhibiting tumor growth (PMID: 25172549).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown connective tissue benign neoplasm not applicable Ipafricept Phase I Actionable In a Phase I trial, two desmoid tumor patients demonstrated stable disease for greater than 6 months when treated with Ipafricept (OMP-54F28) (PMID: 28954784). 28954784
Unknown unknown Advanced Solid Tumor not applicable Ipafricept Phase I Actionable In a Phase I trial, Ipafricept (OMP-54F28) demonstrated safety and preliminary efficacy in patients with advanced solid tumors (J Clin Oncol 32:5s, 2014 (suppl; abstr 2505)). detail...
Unknown unknown germ cell cancer not applicable Ipafricept Phase I Actionable In a Phase I trial, a patient with germ cell cancer demonstrated stable disease for greater than 6 months when treated with Ipafricept (OMP-54F28) (PMID: 28954784). 28954784
Clinical Trial Phase Therapies Title Recruitment Status